Fujisawa T, Yamaguchi Y, Kimura H
Jpn J Surg. 1983 Jul;13(4):304-11. doi: 10.1007/BF02469511.
We studied the transfer factor (TF) with regard to in vivo and in vitro restoration of cell mediated immunity (CMI) in lung cancer patients. Twenty-eight lung cancer patients who had undergone resection were the recipients and 30 household contact family members with a positive reactivity to lung cancer extract were the donors of TF. Immunologic status was evaluated by delayed type cutaneous hypersensitivity (DTH), peripheral T lymphocyte number, PHA lymphocyte blastogenesis, serum blocking activity (SBA) and leucocyte adherence inhibition (LAI) test. When TF was administered twice subcutaneously to the patients, there was a statistically significant restoration or augmentation of DTH, PHA lymphocyte blastogenesis and abrogation of SBA, particularly in patients with suppressed CMI. These results suggest that it was the TF obtained from relatives of lung cancer patients with positive reactivity to tumor associated antigens restored or augmented tumor specific and nonspecific CMI in these lung cancer patients.
我们研究了转移因子(TF)对肺癌患者体内和体外细胞介导免疫(CMI)的恢复作用。28例接受过切除术的肺癌患者作为受体,30名对肺癌提取物反应呈阳性的家庭接触者作为TF的供体。通过迟发型皮肤超敏反应(DTH)、外周血T淋巴细胞数量、PHA淋巴细胞增殖、血清阻断活性(SBA)和白细胞黏附抑制(LAI)试验评估免疫状态。当给患者皮下注射TF两次时,DTH、PHA淋巴细胞增殖有统计学意义的恢复或增强,SBA消除,尤其是在CMI受到抑制的患者中。这些结果表明,从对肿瘤相关抗原有阳性反应的肺癌患者亲属中获得的TF恢复或增强了这些肺癌患者的肿瘤特异性和非特异性CMI。